Akorn

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Akorn Inc.
Public
Traded as
ISINUS0097281069 Edit this on Wikidata
Industrypharmaceutical industry Edit this on Wikidata
FounderJohn Kapoor Edit this on Wikidata
HeadquartersForest Lake, Illinois, U.S.
RevenueIncrease $841 million (2017)
Websitewww.akorn.com/ Edit this on Wikidata

Akorn Inc. is an American generic pharmaceuticals manufacturer based in Lake Forest, Illinois. It is a component of the NASDAQ Biotechnology Index.

History[edit]

John Kapoor is not the founder but has been a major shareholder since the 1990s.[1]

Akorn acquired rival Hi-Tech Pharmacal in 2013.[2]

In June 2015, it was reported that a hacker was trying to sell an Akorn customer database of more than 50,000 records. Akorn commented that "Although much of the information acquired is publicly available, we are in the process of notifying our valued customers about this incident".[3]

In April 2017, Akorn agreed to be acquired by Fresenius for $4.3 billion.[4] These plans were abandoned by Fresenius after Akorn couldn′t meet basic requirements for an acquisition. In October 2018, Akorn received Abbreviated New Drug Application (ANDA) approval from Food and Drug Administration (FDA) for Bimatoprost Ophthalmic Solution, 0.03%.[5]

References[edit]

  1. ^ "John Kapoor". Forbes. Retrieved 12 May 2015.
  2. ^ Reuters Editorial. "Eye drug maker Akorn to buy rival Hi-Tech Pharmacal for $640 million". Reuters. Retrieved 2 August 2017.
  3. ^ "Akorn Inc. has customer database stolen, records offered to highest bidder". CSO. 18 June 2015. Retrieved 28 June 2015.
  4. ^ "Fresenius Buys Akorn for $4.3 Billion in U.S. Expansion". 24 April 2017. Retrieved 23 September 2017 – via www.bloomberg.com.
  5. ^ "Akorn (AKRX) Receives ANDA Approval from FDA for Bimatoprost Ophthalmic Solution, 0.03%". StreetInsider.com. Retrieved 2018-10-23.

External links[edit]